|
|
|
|
|
|
|
|
|
23.07.26 - 22:21
|
Edwards Lifesciences Reports Second Quarter Results (Business Wire)
|
|
|
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.
Highlights
Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5%
Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5%
Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies
Q2 EPS of $0.421; adjusted2 EPS of $0.781
Recent clinical data at New York Valves reinforce best-in-class SAPIEN performance and durability; PASCAL, EVOQUE and SAPIEN M3 differentiated body of clinical evidence continues to expand
2026 Outlook
Increasing total company constant currency2 sales growth guidance: 10% to 11% from 9% to 11%
Increasing TAVR constant currency2 sales growth guidance: 8% to 9% from 7% to 9%
Increasing TMTT sales guidance: $760 to $780 million from $740 to $780 million
Reaffirming adjusted EPS guidance of $2.95 to $3.05, growing 17% at midpoint
Expected clinical presentations at TCT: PROGRESS an...
|
|
|
|
|
16.07.26 - 13:06
|
Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026 (Business Wire)
|
|
|
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.About Edwards LifesciencesEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.Edwards, Edwards Lifesciences, and the stylized E logo ar...
|
|
|
|
|
|
|
|
|
|
|
|
|
16.06.26 - 20:27
|
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device (Benzinga)
|
|
|
CMS proposes easing TAVR coverage rules and expanding access, a move analysts say could strengthen Edwards Lifesciences' market position.
Latest Ratings for EW
DateFirmActionFromTo Feb 2022UBSUpgradesNeutralBuy Jan 2022Morgan StanleyMaintainsOverweight Jan 2022Raymond JamesMaintainsOutperform
View More Analyst Ratings for EW
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.05.26 - 21:15
|
VahatiCor ernennt Dr. Harry D. Rowland zum Chief Executive Officer (Business Wire)
|
|
|
Der Mitbegründer und ehemalige CEO von Endotronix wechselt zu VahatiCor, während das Unternehmen die Entwicklung des A-FLUX Reducer System® sowie die SERRA-I-Studie zur frühen Machbarkeit vorantreibtSANTA CLARA, Kalifornien--(BUSINESS WIRE)--VahatiCor, Inc., ein Medizintechnikunternehmen, das interventionelle Therapien für die koronare mikrovaskuläre Dysfunktion (CMD) entwickelt, gab heute die Ernennung von Harry D. Rowland, Ph.D. zum Chief Executive Officer bekannt.
Rowland war zuvor als Chief Executive Officer und President von Endotronix tätig, wo er die Entwicklung und Vermarktung des Cordella™-Lungenarteriensensors und des Herzinsuffizienz-Systems leitete. Unter seiner Führung beschaffte Endotronix über 150 Millionen US-Dollar und wuchs auf mehr als 150 Mitarbeiter an. Darüber hinaus leitete er die zulassungsrelevante PROACTIVE-HF-Studie von der Durchführung über die FDA-Zulassung bis hin zur Markteinführung. Nach der Übernahme durch Edwards Lifesciences im Jahr 2024 blieb Rowland im ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
